GlycoPath

Glyco Path

Biotechnology, 173 Ashley Ave, Charleston, South Carolina, United States, 1-10 Employees

glycopath.com

  • twitter
  • LinkedIn

Who is GLYCOPATH

At GlycoPath, our mission is to generate new applications utilizing MALDI Mass Spectrometry Imaging to study changes in the glycosylation of various disease states. By generating streamli...

Read More

map
  • 173 Ashley Ave, Charleston, South Carolina, United States Headquarters: 173 Ashley Ave, Charleston, South Carolina, United States
  • 2019 Date Founded: 2019
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GLYCOPATH

GlycoPath Org Chart and Mapping

Employees

Danielle Scott

Chief Officer of Product Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding GlycoPath

Answer: GlycoPath's headquarters are located at 173 Ashley Ave, Charleston, South Carolina, United States

Answer: GlycoPath's official website is https://glycopath.com

Answer: GlycoPath's revenue is Under $1 Million

Answer: GlycoPath's SIC: 2836

Answer: GlycoPath's NAICS: 541714

Answer: GlycoPath has 1-10 employees

Answer: GlycoPath is in Biotechnology

Answer: GlycoPath contact info: Phone number: Website: https://glycopath.com

Answer: At GlycoPath, our mission is to generate new applications utilizing MALDI Mass Spectrometry Imaging to study changes in the glycosylation of various disease states. By generating streamlined methods with proven clinical impact, we hope to introduce accurate simplified assays to improve patient care and treatment. The proprietary GlycoTyper is designed to classify how the glycans, or sugar code on proteins, change during the development of cancer. For decades, the role of glycans and glycoproteins have been evaluated in cancer. Through extensive studies focused on elucidating the biological functions of glycosylation, researchers have been able to implicate alterations in these functions to tumor formation and metastasis. Although this has been studied for many years, the clinical relevance of these studies has been limited due to a lack of clinical assays. The GlycoTyper assay was developed to directly address the need for a more high-throughput method for protein-specific glycan analysis from biological samples. The glycan profiling technology captures diagnostic glycoproteins from blood using antibodies. These captured proteins then undergo direct glycan analysis using MALDI mass spectrometry. In addition to the proprietary GlycoTyper assay, we have created the Basic N-Glycan Imaging Kit. The kit is available for purchase through the website in two sizes (small & large). The Glycopath Basic N-Glycan Imaging Kit gives the researcher the practical expertise and the means to determine the spatial distribution of N-glycans in their lab to enhance their biomedical investigations.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access